Migraine Relief Found in Weight Loss Jabs?

New research presented at the European Congress of Obesity indicates that weight loss injections may significantly reduce the frequency of migraine attacks in women. Danish health registry data revealed that women using semaglutide-based injections, such as Wegovy and Ozempic, required triptan drugs – a primary treatment for migraines – 8% less often. The effect was most pronounced in women aged 18 to 35, who reduced their triptan use by 18%.

Scientists analyzed data from approximately 150,000 individuals who started these injections between 2022 and 2024. Notably, no significant reduction in migraine drug use was observed in men. Researchers hypothesize that the injections, which mimic the hormone GLP-1, might alleviate migraines due to their anti-inflammatory properties or direct effects on the central nervous system's "migraine pathways."

Migraines affect about ten million people in Britain, with women being disproportionately impacted. The study, sponsored by Novo Nordisk, sponsor of Wegovy and Ozempic, followed participants for up to a year after starting the weekly injections. Reliance on triptans decreased gradually, suggesting a sustained effect.

Further confirmation through randomized clinical studies is needed to establish a direct anti-migraine effect beyond weight loss. Experts emphasize that while these findings are promising, more research is required to understand the full potential of GLP-1 agonists in alleviating migraine symptoms, particularly given that migraine is more common in women and can be linked to hormonal fluctuations.